The latest issue of AIDS Treatment News (#288) has been added
to Immunet's complete, fully-searchable & indexed ATN archive
at http://www.***.com/

     ********************

--- New issue features:

  * Organ Transplants: Interview with Jeff Getty, on Ending the
         Exclusion of People with HIV
  * HIV/AIDS in Prison Project Threatened: Interview with
         Judy Greenspan, Director
  * 5th Retroviruses Conference in Chicago
  * Adefovir Dipivoxil (PREVEON(TM)): Expanded Access
         Restrictions Being Eased
  * NTZ Submitted to FDA for Cryptosporidiosis

     ********************

You can read this and every previous issue of AIDS Treatment News at
http://www.***.com/ .  The Immunet site features a sophisticated
search engine to simplify access to over 11 years of AIDS Treatment News
articles.
Also featured is John S. James' helpful personal index.

====================================================
***  About AIDS TREATMENT NEWS  ***                
====================================================

AIDS TREATMENT NEWS is one of the primary treatment resources for AIDS
and HIV.  It reports on experimental and standard treatments, especially
those available now, and has been published twice monthly, continuously
since 1986 by John S. James.

AIDS TREATMENT NEWS interviews physicians, scientists, other health
professionals, and persons with AIDS or HIV.  They also collect
information from meetings and conferences, medical journals, and
computer databases. Long-term survivors have usually tried many
different treatments, and found combinations which work for them.
AIDS TREATMENT NEWS does not recommend particular therapies, but
seeks to increase the options available.

AIDS TREATMENT NEWS is funded by subscriptions and contributions and
does not accept contributions from pharmaceutical companies or others
whose products they might cover.

-----------------------------------------------------------------------------
* Immunet -- a non profit AIDS Service Organization
* http://www.***.com/

-----------------------------------------------------------------------------